Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03692871 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,409
- Enrollment target
NCT03692871 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 2,409 participants.
The verdict
NCT03692871, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,409 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and tolerability of V114 and Prevnar 13™ in healthy infants. This study will include both full-term infants (≥37 weeks gestational age) and premature infants (\<37 weeks gestational age). Premature infants will be included in a Premature Infant Immunogenicity Substudy, which will assess immunogenicity and safety following administration of V114 or Prevnar 13™.
Interventions
- BIOLOGICAL V114
- BIOLOGICAL Prevnar 13™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,409 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2021-03-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03692871
The ClinicalTrials.gov registry entry for NCT03692871 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,409 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which V114 is the first listed.
NCT03692871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03692871 about?
NCT03692871 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)". This study is designed to evaluate the safety and tolerability of V114 and Prevnar 13™ in healthy infants. This study will include both full-term infants (≥37 weeks gestational age) and premature infants (\<37 weeks gestational age). Premature infants will be included in a Premature Infant Immunogen...
What is the current status of trial NCT03692871?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,409 participants. The study started on 2018-12-14. Estimated completion is 2021-03-26.
What interventions are being tested in trial NCT03692871?
The interventions under investigation include: V114 (BIOLOGICAL), Prevnar 13™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT03692871?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.